Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines

Masashi Ando, Masaru Narabayashi, Toru Watanabe, Yoshikazu Kamiya, Kazuto Togitani, Ryuji Tanosaki, Takeaki Takenaka, Kensei Tobinai, Isamu Adachi

研究成果: Article

13 引用 (Scopus)

抄録

Background: Accumulation of data regarding therapy-related leukemia (TRL) or myelodysplastic syndrome (t-MDS) is critical for assessing the risk of developing such diseases and for subsequent decision-making processes for better treatment. Methods: We evaluated the clinical characteristics of patients with TRLVt-MDS diagnosed at the National Cancer Center Hospital between January 1989 and September 1997. This report is concerned with those patients who initially had been treated with chemotherapeutic agents for breast cancer. Results: Thirteen patients (median age, 55 years) developed TRL (n = 4) or t-MDS (n = 9). The median interval between the development of TRL/t-MDS and initial treatment was 94 months (range 23-190 months). For the primary therapy, all patients had received intense and prolonged treatment with cyclophosphamide (CPA) and/or anthracyclines including doxorubicin (DOX), with a median cumulative dose of 55 g/body (range 16.4-288.5 g) for CPA and 480 mg/m2 (range 395-625.5 mg/m2) for DOX. Seven patients were subsequently treated by chemotherapy and one received an allogeneic bone marrow transplantation. Conclusions: Clinicians must remain alert to the risks associated with unproven medical practices which include long-term administration of alkylating agents. Selected patients with TRL/t-MDS may respond to intense salvage combination chemotherapy.

元の言語English
ページ(範囲)28-32
ページ数5
ジャーナルJapanese Journal of Clinical Oncology
29
発行部数1
出版物ステータスPublished - 1999 1
外部発表Yes

Fingerprint

Anthracyclines
Myelodysplastic Syndromes
Cyclophosphamide
Leukemia
Breast Neoplasms
Therapeutics
Doxorubicin
Cancer Care Facilities
Alkylating Agents
Homologous Transplantation
Combination Drug Therapy
Bone Marrow Transplantation
Decision Making
Drug Therapy

ASJC Scopus subject areas

  • Oncology

これを引用

Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. / Ando, Masashi; Narabayashi, Masaru; Watanabe, Toru; Kamiya, Yoshikazu; Togitani, Kazuto; Tanosaki, Ryuji; Takenaka, Takeaki; Tobinai, Kensei; Adachi, Isamu.

:: Japanese Journal of Clinical Oncology, 巻 29, 番号 1, 01.1999, p. 28-32.

研究成果: Article

Ando, M, Narabayashi, M, Watanabe, T, Kamiya, Y, Togitani, K, Tanosaki, R, Takenaka, T, Tobinai, K & Adachi, I 1999, 'Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines', Japanese Journal of Clinical Oncology, 巻. 29, 番号 1, pp. 28-32.
Ando, Masashi ; Narabayashi, Masaru ; Watanabe, Toru ; Kamiya, Yoshikazu ; Togitani, Kazuto ; Tanosaki, Ryuji ; Takenaka, Takeaki ; Tobinai, Kensei ; Adachi, Isamu. / Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. :: Japanese Journal of Clinical Oncology. 1999 ; 巻 29, 番号 1. pp. 28-32.
@article{7e8c5c3388c941e3b7cedcb276fd99b3,
title = "Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines",
abstract = "Background: Accumulation of data regarding therapy-related leukemia (TRL) or myelodysplastic syndrome (t-MDS) is critical for assessing the risk of developing such diseases and for subsequent decision-making processes for better treatment. Methods: We evaluated the clinical characteristics of patients with TRLVt-MDS diagnosed at the National Cancer Center Hospital between January 1989 and September 1997. This report is concerned with those patients who initially had been treated with chemotherapeutic agents for breast cancer. Results: Thirteen patients (median age, 55 years) developed TRL (n = 4) or t-MDS (n = 9). The median interval between the development of TRL/t-MDS and initial treatment was 94 months (range 23-190 months). For the primary therapy, all patients had received intense and prolonged treatment with cyclophosphamide (CPA) and/or anthracyclines including doxorubicin (DOX), with a median cumulative dose of 55 g/body (range 16.4-288.5 g) for CPA and 480 mg/m2 (range 395-625.5 mg/m2) for DOX. Seven patients were subsequently treated by chemotherapy and one received an allogeneic bone marrow transplantation. Conclusions: Clinicians must remain alert to the risks associated with unproven medical practices which include long-term administration of alkylating agents. Selected patients with TRL/t-MDS may respond to intense salvage combination chemotherapy.",
keywords = "Breast cancer, Cyclophosphamide, Myelodysplastic syndrome, Therapy-related leukemia",
author = "Masashi Ando and Masaru Narabayashi and Toru Watanabe and Yoshikazu Kamiya and Kazuto Togitani and Ryuji Tanosaki and Takeaki Takenaka and Kensei Tobinai and Isamu Adachi",
year = "1999",
month = "1",
language = "English",
volume = "29",
pages = "28--32",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines

AU - Ando, Masashi

AU - Narabayashi, Masaru

AU - Watanabe, Toru

AU - Kamiya, Yoshikazu

AU - Togitani, Kazuto

AU - Tanosaki, Ryuji

AU - Takenaka, Takeaki

AU - Tobinai, Kensei

AU - Adachi, Isamu

PY - 1999/1

Y1 - 1999/1

N2 - Background: Accumulation of data regarding therapy-related leukemia (TRL) or myelodysplastic syndrome (t-MDS) is critical for assessing the risk of developing such diseases and for subsequent decision-making processes for better treatment. Methods: We evaluated the clinical characteristics of patients with TRLVt-MDS diagnosed at the National Cancer Center Hospital between January 1989 and September 1997. This report is concerned with those patients who initially had been treated with chemotherapeutic agents for breast cancer. Results: Thirteen patients (median age, 55 years) developed TRL (n = 4) or t-MDS (n = 9). The median interval between the development of TRL/t-MDS and initial treatment was 94 months (range 23-190 months). For the primary therapy, all patients had received intense and prolonged treatment with cyclophosphamide (CPA) and/or anthracyclines including doxorubicin (DOX), with a median cumulative dose of 55 g/body (range 16.4-288.5 g) for CPA and 480 mg/m2 (range 395-625.5 mg/m2) for DOX. Seven patients were subsequently treated by chemotherapy and one received an allogeneic bone marrow transplantation. Conclusions: Clinicians must remain alert to the risks associated with unproven medical practices which include long-term administration of alkylating agents. Selected patients with TRL/t-MDS may respond to intense salvage combination chemotherapy.

AB - Background: Accumulation of data regarding therapy-related leukemia (TRL) or myelodysplastic syndrome (t-MDS) is critical for assessing the risk of developing such diseases and for subsequent decision-making processes for better treatment. Methods: We evaluated the clinical characteristics of patients with TRLVt-MDS diagnosed at the National Cancer Center Hospital between January 1989 and September 1997. This report is concerned with those patients who initially had been treated with chemotherapeutic agents for breast cancer. Results: Thirteen patients (median age, 55 years) developed TRL (n = 4) or t-MDS (n = 9). The median interval between the development of TRL/t-MDS and initial treatment was 94 months (range 23-190 months). For the primary therapy, all patients had received intense and prolonged treatment with cyclophosphamide (CPA) and/or anthracyclines including doxorubicin (DOX), with a median cumulative dose of 55 g/body (range 16.4-288.5 g) for CPA and 480 mg/m2 (range 395-625.5 mg/m2) for DOX. Seven patients were subsequently treated by chemotherapy and one received an allogeneic bone marrow transplantation. Conclusions: Clinicians must remain alert to the risks associated with unproven medical practices which include long-term administration of alkylating agents. Selected patients with TRL/t-MDS may respond to intense salvage combination chemotherapy.

KW - Breast cancer

KW - Cyclophosphamide

KW - Myelodysplastic syndrome

KW - Therapy-related leukemia

UR - http://www.scopus.com/inward/record.url?scp=0032603981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032603981&partnerID=8YFLogxK

M3 - Article

C2 - 10073148

AN - SCOPUS:0032603981

VL - 29

SP - 28

EP - 32

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

ER -